Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies
Joe N. Kornegay(Texas A&M University), Eric P. Hoffman(Binghamton University), Zheng Fan(China Pharmaceutical University), Martin K. Childers(University of Washington), Daniel J. Bogan(University of North Carolina at Chapel Hill), Robert W. Grange(Virginia Tech), Bruce P. Keene(North Carolina State University), James F. Howard(University of North Carolina at Chapel Hill), Ratna Bhavaraju‐Sanka(The University of Texas Health Science Center at San Antonio), Kevin M. Flanigan(Nationwide Children's Hospital), C.A. Larsen(University of Utah), Martin Styner(University of North Carolina at Chapel Hill), Peter P. Nghiem(Texas A&M University), Scott J. Schatzberg(Georgia College & State University), Juan Li(Chinese PLA General Hospital), Jiahui Wang(Qingdao Agricultural University), Xiao Xiao(Qingdao University), Janet R. Bogan(University of North Carolina at Chapel Hill), Sandra Tou(North Carolina State University), David A. Detwiler(University of North Carolina at Chapel Hill)
Cited by 178
Related Papers
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
|The Lancet Neurology|2017|820
Evidence‐based path to newborn screening for duchenne muscular dystrophy
|Annals of Neurology|2012|816
Eteplirsen for the treatment of Duchenne muscular dystrophy
|Annals of Neurology|2013|793
Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis
|Oncogenesis|2017|707
Distinctive patterns of microRNA expression in primary muscular disorders
|Proceedings of the National Academy of Sciences|2007|509